University of California, Los Angeles |
Frank Pajonk |
Quest - Discovery Stage Research Projects |
Development of novel small molecules against cancer stem cells in solid cancers |
$2,340,000 |
University of California, Los Angeles |
Richard Pietras |
Quest - Discovery Stage Research Projects |
Reversal of dysregulated myelopoiesis in breast cancers and cancer stem cells to boost antitumor immunotherapy |
$2,327,680 |
University of California, Los Angeles |
Song Li |
Quest - Discovery Stage Research Projects |
Vax-CT to promote formation of cancer-specific T memory stem cell for personalized cancer immunotherapy |
$2,267,714 |
University of California, San Francisco |
Robert Blelloch |
Foundation - Discovery Stage Research Projects |
Development of universal off-the-shelf iPSC derived dendritic cells for use as patient specific anti-tumor vaccine |
$1,391,999 |
University of California, San Diego |
Michael Karin |
Quest - Discovery Stage Research Projects |
Targeting pancreatic cancer stem cells with DDR1 antibodies. |
$1,425,600 |
University of California, Los Angeles |
Dinesh Rao |
Quest - Discovery Stage Research Projects |
Novel methods to eliminate cancer stem cells |
$1,384,347 |
University of California, Los Angeles |
Lili Yang |
Quest - Discovery Stage Research Projects |
Combating Ovarian Cancer Using Stem Cell-Engineered Off-The-Shelf CAR-iNKT Cells |
$1,404,000 |
University of California, Irvine |
Michael Demetriou |
Quest - Discovery Stage Research Projects |
CAR T cells targeting abnormal N-glycans for the treatment of refractory/metastatic solid cancers |
$1,414,800 |
University of California, San Francisco |
Julia Carnevale |
Quest - Discovery Stage Research Projects |
Generating deeper and more durable BCMA CAR T cell responses in Multiple Myeloma through non-viral knockin/knockout multiplexed genome engineering |
$1,463,368 |
Stanford University |
Ansuman Satpathy |
Quest - Discovery Stage Research Projects |
Preclinical development of an exhaustion-resistant CAR-T stem cell for cancer immunotherapy |
$1,420,200 |
Cytonus Therapeutics, Inc. |
Edward Filardo |
Quest - Discovery Stage Research Projects |
Development of a novel stem-cell based carrier for intravenous delivery of oncolytic viruses |
$899,342 |
University of California, San Diego |
Tannishtha Reya |
Quest - Discovery Stage Research Projects |
Targeting Critical Regulators of Cancer Stem Cells |
$1,148,264 |
University of California, Irvine |
Munjal Acharya |
Quest - Discovery Stage Research Projects |
Stem cell-derived extracellular vesicles to reverse radiation-induced brain injury |
$1,064,724 |
University of California, San Diego |
Dan Kaufman |
Quest - Discovery Stage Research Projects |
Human iPSC-derived chimeric antigen receptor expressing macrophages for improved cancer treatment. |
$1,256,332 |
University of California, San Diego |
Dan Kaufman |
Quest - Discovery Stage Research Projects |
Human iPSC-derived chimeric antigen receptor-expressing macrophages for cancer treatment |
$222,200 |
Stanford University |
Philip Beachy |
Quest - Discovery Stage Research Projects |
Pluripotent stem cell-derived bladder epithelial progenitors for definitive cell replacement therapy of bladder cancer |
$1,265,436 |
University of California, San Francisco |
Hideho Okada |
Quest - Discovery Stage Research Projects |
Non-viral reprogramming of the endogenous TCRα locus to direct stem memory T cells against shared neoantigens in malignant gliomas |
$900,000 |
City of Hope, Beckman Research Institute |
Saul Priceman |
Quest - Discovery Stage Research Projects |
Chimeric Antigen Receptor-Engineered Stem/Memory T Cells for the Treatment of Recurrent Ovarian Cancer |
$1,351,174 |
University of California, Los Angeles |
Lili Yang |
Quest - Discovery Stage Research Projects |
Preclinical Development of An HSC-Engineered Off-The-Shelf iNKT Cell Therapy for Cancer |
$1,404,000 |
University of California, San Diego |
Tannishtha Reya |
Quest - Discovery Stage Research Projects |
Targeting Cancer Stem Cells in Hematologic Malignancies |
$1,960,560 |
Human BioMolecular Research Institute |
John Cashman |
Inception - Discovery Stage Research Projects |
Human Pancreatic Cancer Stem Cells: Developing a Novel Drug for Cancer Eradication |
$303,785 |
Loma Linda University |
Julia Unternaehrer-Hamm |
Inception - Discovery Stage Research Projects |
Targeting cancer stem cells with nanoparticle RNAi delivery to prevent recurrence and metastasis of ovarian cancer |
$172,870 |
Loma Linda University |
David Baylink |
Inception - Discovery Stage Research Projects |
Bone Marrow Targeting of Hematopoietic Stem Cells Engineered to Overexpress 25-OH-VD3 1-α-hydroxylase for Acute Myeloid Leukemia Therapy |
$178,967 |
University of California, San Diego |
Yuan Chen |
Quest - Discovery Stage Research Projects |
A Novel Approach to Eradicate Cancer Stem Cells |
$279,977 |
City of Hope, Beckman Research Institute |
Markus Müschen |
Quest - Discovery Stage Research Projects |
Lgr5-mediated self-renewal in B cell selection and leukemia-initiation |
$2,186,520 |
City of Hope, Beckman Research Institute |
Yuan Chen |
Quest - Discovery Stage Research Projects |
A Novel Approach to Eradicate Cancer Stem Cells |
$1,539,935 |
University of California, Los Angeles |
Gay Crooks |
Quest - Discovery Stage Research Projects |
Platform Technology for Pluripotent Stem Cell-Derived T cell Immunotherapy |
$965,636 |
University of California, San Diego |
Dan Kaufman |
Quest - Discovery Stage Research Projects |
Targeted off-the-shelf immunotherapy to treat refractory cancers |
$1,936,936 |
University of California, Los Angeles |
John Chute |
Quest - Discovery Stage Research Projects |
Protein tyrosine phosphatase - sigma inhibitors for hematopoietic regeneration |
$2,115,735 |
Stanford University |
Hiromitsu Nakauchi |
Quest - Discovery Stage Research Projects |
Novel Rejuvenated T Cell Immunotherapy for Lung Cancer |
$1,968,456 |
University of California, Berkeley |
Jacob Corn |
Inception - Discovery Stage Research Projects |
Genome editing for causation and reversion of MPN-associated mutations in human hematopoietic stem cells |
$235,800 |
University of California, Los Angeles |
Owen Witte |
Inception - Discovery Stage Research Projects |
Identification of stem cell surface markers as potential therapeutic targets for advanced prostate cancer |
$209,160 |
Stanford University |
Philip Beachy |
Inception - Discovery Stage Research Projects |
Curing bladder cancer by replacing corrupted urothelium with differentiated hES cells |
$210,906 |
University of California, Los Angeles |
John Chute |
Research Leadership |
Niche-Focused Research: Discovery & Development of Hematopoietic Regenerative Factors |
$4,645,297 |
University of California, San Diego |
David Cheresh |
Basic Biology V |
CD61-driven stemness program in epithelial cancer |
$1,161,000 |
University of California, Los Angeles |
Robert Reiter |
Early Translational IV |
Clinical Development of an N-cadherin Antibody to Target Cancer Stem Cells |
$4,075,668 |
University of California, San Francisco |
Ann Zovein |
New Faculty Physician Scientist |
Human endothelial reprogramming for hematopoietic stem cell therapy. |
$2,197,683 |
Stanford University |
Michelle Monje |
New Faculty Physician Scientist |
White matter neuroregeneration after chemotherapy: stem cell therapy for “chemobrain” |
$2,800,526 |
Stanford University |
Michael Cleary |
Basic Biology IV |
Prostaglandin pathway regulation of self-renwal in hematopoietic and leukemia stem cells |
$1,244,455 |
University of California, Los Angeles |
Owen Witte |
Basic Biology IV |
Trop2 dependent and independent mechanisms of self-renewal in human cancer stem cells |
$1,254,960 |
City of Hope, Beckman Research Institute |
Stephen Forman |
Early Translational III |
Targeting glioma cancer stem cells with receptor-engineered self-renewing memory T cells |
$5,215,447 |
University of California, Los Angeles |
Noriyuki Kasahara |
Early Translational II |
Stem cell-based carriers for RCR vector delivery to glioblastoma |
$3,340,625 |
University of California, San Diego |
Catriona Jamieson |
Early Translational II |
Preclinical development of a pan Bcl2 inhibitor for cancer stem cell directed therapy |
$3,103,041 |
University of California, San Francisco |
Markus Muschen |
Early Translational II |
Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication |
$2,756,536 |
Children's Hospital of Los Angeles |
Markus Muschen |
Early Translational II |
Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication |
$850,769 |
Sanford Burnham Prebys Medical Discovery Institute |
Robert Wechsler-Reya |
Research Leadership |
The role of neural stem cells in cerebellar development, regeneration and tumorigenesis |
$5,226,049 |
University of California, Los Angeles |
Antoni Ribas |
New Faculty II |
Stem Cells for Immune System Regeneration to Fight Cancer |
$3,072,000 |
University of California, Los Angeles |
Brigitte Gomperts |
New Faculty II |
Stem Cells in Lung Cancer |
$2,381,572 |
University of California, San Diego |
Catriona Jamieson |
New Faculty II |
Derivation and Characterization of Myeloproliferative Disorder Stem Cells from Human ES Cells |
$3,065,572 |
University of California, San Francisco |
Emmanuelle Passegue |
New Faculty II |
Mechanisms Underlying the Responses of Normal and Cancer Stem Cells to Environmental and Therapeutic Insults |
$2,124,488 |
University of California, Los Angeles |
Zack Jerome |
New Cell Lines |
Generation of clinical grade human iPS cells |
$1,341,000 |
University of California, Los Angeles |
Siavash Kurdistani |
New Faculty I |
Epigenetics in cancer stem cell initiation and clinical outcome prediction |
$3,063,450 |
University of California, Los Angeles |
Hanna Mikkola |
New Faculty I |
Mechanisms of Hematopoietic stem cell Specification and Self-Renewal |
$2,286,900 |
University of California, Davis |
Chong-Xian Pan |
New Faculty I |
Combinatorial Chemistry Approaches to Develop LIgands against Leukemia Stem Cells |
$2,386,409 |
University of California, San Diego |
Yang Xu |
Comprehensive Grant |
Mechanisms to maintain the self-renewal and genetic stability of human embryonic stem cells |
$2,467,200 |
University of California, Los Angeles |
Zoran Galic |
SEED Grant |
Genetic Enhancement of the Immune Response to Melanoma via hESC-derived T cells |
$616,800 |
City of Hope, Beckman Research Institute |
Timothy O'Connor |
SEED Grant |
Sources of Genetic Instability in Human Embryonic Stem Cells. |
$327,311 |
University of California, San Francisco |
Thea Tlsty |
SEED Grant |
Role of the tumor suppressor gene, p16INK4a, in regulating stem cell phenotypes in embryonic stem cells and human epithelial cells. |
$614,784 |
University of Southern California |
Peter Laird |
SEED Grant |
Screening for Oncogenic Epigenetic Alterations in Human ES Cells |
$647,431 |
Gladstone Institutes, J. David |
Warner Greene |
SEED Grant |
The APOBEC3 Gene Family as Guardians of Genome Stability in Human Embryonic Stem Cells |
$717,363 |
University of California, Irvine |
Charles Limoli |
SEED Grant |
Using human embryonic stem cells to treat radiation-induced stem cell loss: Benefits vs cancer risk |
$593,242 |
Children's Hospital of Los Angeles |
Elizabeth Lawlor |
SEED Grant |
hESC as tools to investigate the neural crest origin of Ewing's sarcoma |
$595,576 |
Stanford University |
Julien Sage |
SEED Grant |
Functions of RB family proteins in human embryonic stem cells |
$498,609 |
University of California, San Diego |
Catriona Jamieson |
SEED Grant |
Derivation and Characterization of Cancer Stem Cells from Human ES Cells |
$616,305 |